Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 3/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | CTSE | P14091 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19838919 | 1.00 | KMT2A (0.39) | KMT2AMEN1GRIN2BGRIN2CALDH1A1 | |
| SCHEMBL19838985 | 0.93 | TSHR (0.38) | KMT2AMEN1ALDH1A1LMNABACE1 | |
| SCHEMBL19838987 | 0.93 | TSHR (0.38) | KMT2AMEN1ALDH1A1LMNABACE1 | |
| SCHEMBL19853389 | 0.93 | TSHR (0.38) | KMT2AMEN1ALDH1A1LMNABACE1 | |
| SCHEMBL19853462 | 0.88 | MEN1 (0.38) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL19838997 | 0.88 | MEN1 (0.38) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL22085798 | 0.88 | KMT2A (0.42) | KMT2AMEN1GRIN2BGRIN2CALDH1A1 | |
| SCHEMBL19838968 | 0.82 | OPRM1 (0.38) | KMT2AMEN1ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL19838967 | 0.82 | OPRM1 (0.38) | KMT2AMEN1ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL19853303 | 0.80 | MMP1 (0.41) | KMT2AMEN1ALDH1A1LMNABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3490994-B1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-09-01 | — | — | US | disclosed |
| CN-109661398-B | Spiro-lactam and di-spiro-lactam NMDA receptor modulators and uses thereof | 阿普廷伊克斯股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20220098211-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. | 2022-03-31 | — | — | US | disclosed |
| US-11028095-B2 | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028095-B2 | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2021021996-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | APTINYX INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20200181159-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2020-06-11 | — | — | US | disclosed |
| US-20200181159-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2020-06-11 | — | — | US | disclosed |
| WO-2018026792-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181159-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | KMT2A 1813/4885MEN1 3237/4885GRIN2B 4/4885 |
| US-20220098211-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | KMT2A 1813/4885MEN1 3237/4885GRIN2B 4/4885 |
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | GRIN2A, GRIN2B, GRIN1 | KMT2A 1340/4885MEN1 949/4885GRIN2B 2/4885 |
| US-11028095-B2 | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | KMT2A 1813/4885MEN1 3237/4885GRIN2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.